Einherjar wrote: While I enjoy toying with this idea I am open for suggestions of alternate ways to go about the issue.
Actually, I am less skeptical about it after debating it with you than I was on hearing about the idea for the first time. Having considered your explanations, I am left with no clear-cut reason why this
cannot possibly work. I'm not ready to endorse your idea yet either, but my opposition is now down to gut feelings like: If government uses some mechanical rule to buy up patents above market price, businesses will find a way to game the system and conspire to raise the market price -- perhaps with dummy bidders for the patents. Or: If government buys up patents at its discretion above market prices, the people who run the responsible government agency will somehow use the discretion to give kickbacks to favored businesses while withholding them from others. But I admit that at this point, I can't suggest an exploit of your system that would be obvious and severe enough to prove my point.
On a different note, I have browsed the income statements of other, non-pharmaceutical Fortune 500 companies. Looking at their ratios of "R&D" to "Selling, General, Administration", it turns out the value is in the same ball park whether they deal in pharmaceuticals (cited above), airospace (Boeing), IT (Lucent, Intel, Cisco, Microsoft), materials (3M) or are conglomerates (Siemens). And like George says, "Selling, General, Administration" appears to be a catch-all that cover some R&D costs for at least some companies. For example, the R&D entry in General Electric's income statement is empty, which certainly understates how much this conglomerate is actually spending on research and development. Based on these observations, I doubt that pharmaceutical companies are actually spending unusually high sums on marketing, compared to other sectors of the economy.